palmitoylethanolamide.com.au
HomeResearchNobili 2024

Ultramicronized N-palmitoylethanolamine associated with analgesics: Effects against persistent pain

Nobili S, Micheli L, Lucarini E, Toti A, Ghelardini C, Di Cesare Mannelli L. Pharmacol Ther. 2024;258:108649.

ReviewHumansOther animals

Design
Review
Subjects
Narrative review of preclinical and clinical studies
Dose used in the study
Not applicable
Duration
Not applicable
What was measured
Pharmacokinetic and pharmacodynamic data on ultramicronised palmitoylethanolamide, its use as an add-on to analgesics, and animal data on limiting opioid tolerance

What the authors reported

Micron-size forms have higher oral efficacy than plain powder, cross the gut wall and blood-brain barrier, and can be used as an add-on to analgesics, with animal data showing they limit opioid tolerance.

Limits of this study

Narrative. Two authors received a grant from Epitech, which makes the ultramicronised product the review favours. The claim of superior oral efficacy over plain powder rests on animal data; see the micronised page.

Source

PubMed 38615798 · doi:10.1016/j.pharmthera.2024.108649

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.